{"id":51992,"date":"2022-12-14T19:02:11","date_gmt":"2022-12-14T18:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/"},"modified":"2022-12-14T19:02:11","modified_gmt":"2022-12-14T18:02:11","slug":"the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/","title":{"rendered":"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups &#8211; Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/3942639\/the-corporate-reputation-of-pharma-in-2021-the?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rkcx2c&amp;utm_campaign=1789815+-+The+Corporate+Reputation+of+Pharma+in+2021-2022%3A+The+Views+of+303+Rare-Disease+Patient+Groups+-+Roche+Ranked+1st%2C+Pfizer+in+2nd+and+Horizon+Therapeutics+in+3rd&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;The Corporate Reputation of Pharma in 2021 &#8211; the Patient Perspective &#8211; Rare Disease Edition &#8211; The Views of 303 Rare-Disease Patient Groups&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe &#8216;Corporate Reputation of Pharma&#8217; survey- rare-disease edition, is now in its 3rd year, and two years into the Covid-19 pandemic.\n<\/p>\n<p>\nBetween November 2021-February 2022, the survey collected the opinions of 303 rare-disease patient groups on the performance of the pharmaceutical industry during 2021, including 56 patient groups focused on bleeding disorders.\n<\/p>\n<p>\nPatient groups-and rare-disease patient groups especially-possess a deep and unique understanding of the patients they represent and can express the collated views of these patients. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct (as well as into the evaluation of clinical outcomes).\n<\/p>\n<p>\nAt the same time, many patient groups are also familiar with the complexities of the pharmaceutical industry&#8217;s business. From their vantage point, therefore, patient groups are both able to assess pharma, and recommend ways in which companies can improve-all from a patient perspective.\n<\/p>\n<p>\n<strong>The report provides details on:<\/strong>\n<\/p>\n<ul>\n<li>\nHow the analyst measures pharma&#8217;s corporate reputation from a patient perspective;\n<\/li>\n<li>\nThe companies included in the 2021 rare-disease analysis;\n<\/li>\n<li>\nThe headline results of the 2021 survey, from the perspective of rare-disease patient groups; and\n<\/li>\n<li>\nThe profiles of 2021&#8217;s respondent rare-disease patient groups.\n<\/li>\n<\/ul>\n<p>\n<strong>Profiles of the 32 companies<\/strong>\n<\/p>\n<ul>\n<li>\nAbbVie\n<\/li>\n<li>\nAmgen\n<\/li>\n<li>\nAstellas Pharma\n<\/li>\n<li>\nAstraZeneca\n<\/li>\n<li>\nBayer\n<\/li>\n<li>\nBiogen\n<\/li>\n<li>\nBoehringer Ingelheim\n<\/li>\n<li>\nBristol Myers Squibb\n<\/li>\n<li>\nChiesi Farmaceutici\n<\/li>\n<li>\nCSL Behring\n<\/li>\n<li>\nEli Lilly\n<\/li>\n<li>\nGilead Sciences\n<\/li>\n<li>\nGrifols\n<\/li>\n<li>\nGSK\n<\/li>\n<li>\nHorizon Therapeutics\n<\/li>\n<li>\nIpsen\n<\/li>\n<li>\nJanssen\n<\/li>\n<li>\nLundbeck\n<\/li>\n<li>\nMerck &amp; Co\n<\/li>\n<li>\nMerck KGaA\n<\/li>\n<li>\nMylan\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nNovo Nordisk\n<\/li>\n<li>\nOctapharma\n<\/li>\n<li>\nPfizer\n<\/li>\n<li>\nRoche\n<\/li>\n<li>\nSandoz\n<\/li>\n<li>\nSanofi\n<\/li>\n<li>\nTakeda\n<\/li>\n<li>\nTeva\n<\/li>\n<li>\nUCB\n<\/li>\n<li>\nVertex\n<\/li>\n<\/ul>\n<p>\n<strong>COMPANY RANKINGS &#8211; ALL RARE-DISEASES<\/strong>\n<\/p>\n<ul>\n<li>\nThe top-three pharma companies out of 32 companies, ranked for their overall corporate reputation in 2021, assessed by respondent rare-disease patient groups familiar with the company: Roche, 1st &#8211; Pfizer, 2nd &#8211; Horizon Therapeutics, 3rd.\n<\/li>\n<li>\nThe top-three pharma companies out of 18 companies, ranked for their overall corporate reputation in 2021, assessed by respondent rare-disease patient groups working with the company: Roche, 1st &#8211; Pfizer, 2nd &#8211; Horizon Therapeutics, 3rd.\n<\/li>\n<li>\nThe top-three &#8216;big-pharma&#8217; companies out of 13 companies, ranked for their overall corporate reputation in 2021, assessed by respondent rare-disease patient groups familiar with the company: Roche, 1st &#8211; Pfizer, 2nd &#8211; Takeda, 3rd.\n<\/li>\n<li>\nThe top-three pharma companies out of 8 companies, ranked for their overall corporate reputation in 2021, assessed by respondent rare-disease patient groups working with the company: Roche, 1st &#8211; Pfizer, 2nd &#8211; Sanofi, 3rd.\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<ul>\n<li>\nExecutive summary\n<\/li>\n<li>\nRelationships that rare-disease patient groups have with pharma, 2021\n<\/li>\n<li>\nIndustry-wide findings for rare diseases, 2021\n<\/li>\n<li>\nRankings of 32 pharma companies, 2021 v. 2020, as assessed by respondent rare-disease patient groups familiar with the companies\n<\/li>\n<li>\nRankings of 18 pharma companies, 2021 v. 2020, as assessed by respondent rare-disease patient groups working with the companies\n<\/li>\n<li>\nRankings of 13 &#8216;big-pharma&#8217; companies, 2021 v. 2020, as assessed by respondent rare-disease patient groups familiar with the companies\n<\/li>\n<li>\nRankings of 8 &#8216;big-pharma&#8217; companies, 2021 v. 2020, as assessed by respondent rare-disease patient groups working with the companies\n<\/li>\n<li>\nProfiles of the 32 companies, 2021 (v. 2020)\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/3942639\/the-corporate-reputation-of-pharma-in-2021-the?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rkcx2c&amp;utm_campaign=1789815+-+The+Corporate+Reputation+of+Pharma+in+2021-2022%3A+The+Views+of+303+Rare-Disease+Patient+Groups+-+Roche+Ranked+1st%2C+Pfizer+in+2nd+and+Horizon+Therapeutics+in+3rd&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/c36f96<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#111;&#58;&#112;&#114;ess&#x40;&#x72;&#x65;&#x73;&#x65;&#x61;&#114;&#99;&#104;and&#x6d;&#x61;&#x72;&#x6b;&#x65;&#x74;&#115;&#46;&#99;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">p&#114;&#101;&#x73;&#x73;&#x40;&#x72;e&#115;&#101;&#97;&#x72;&#x63;&#x68;an&#100;&#109;&#x61;&#x72;&#x6b;et&#115;&#46;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; the Patient Perspective &#8211; Rare Disease Edition &#8211; The Views of 303 Rare-Disease Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; survey- rare-disease edition, is now in its 3rd year, and two years into the Covid-19 pandemic. Between November &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51992","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; the Patient Perspective &#8211; Rare Disease Edition &#8211; The Views of 303 Rare-Disease Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; survey- rare-disease edition, is now in its 3rd year, and two years into the Covid-19 pandemic. Between November ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-14T18:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups &#8211; Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-12-14T18:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/\"},\"wordCount\":575,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005880\\\/en\\\/1665175\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/\",\"name\":\"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005880\\\/en\\\/1665175\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-12-14T18:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005880\\\/en\\\/1665175\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005880\\\/en\\\/1665175\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups &#8211; Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; the Patient Perspective &#8211; Rare Disease Edition &#8211; The Views of 303 Rare-Disease Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; survey- rare-disease edition, is now in its 3rd year, and two years into the Covid-19 pandemic. Between November ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-14T18:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups &#8211; Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd &#8211; ResearchAndMarkets.com","datePublished":"2022-12-14T18:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/"},"wordCount":575,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/","name":"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups - Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg","datePublished":"2022-12-14T18:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221214005880\/en\/1665175\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/the-corporate-reputation-of-pharma-in-2021-2022-the-views-of-303-rare-disease-patient-groups-roche-ranked-1st-pfizer-in-2nd-and-horizon-therapeutics-in-3rd-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"The Corporate Reputation of Pharma in 2021-2022: The Views of 303 Rare-Disease Patient Groups &#8211; Roche Ranked 1st, Pfizer in 2nd and Horizon Therapeutics in 3rd &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51992"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51992\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}